ATE362374T1 - Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust - Google Patents

Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust

Info

Publication number
ATE362374T1
ATE362374T1 AT00955737T AT00955737T ATE362374T1 AT E362374 T1 ATE362374 T1 AT E362374T1 AT 00955737 T AT00955737 T AT 00955737T AT 00955737 T AT00955737 T AT 00955737T AT E362374 T1 ATE362374 T1 AT E362374T1
Authority
AT
Austria
Prior art keywords
compositions
methods
cancer
bone loss
preventing
Prior art date
Application number
AT00955737T
Other languages
English (en)
Inventor
Colin Dunstan
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ATE362374T1 publication Critical patent/ATE362374T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT00955737T 1999-09-03 2000-08-18 Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust ATE362374T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38954599A 1999-09-03 1999-09-03

Publications (1)

Publication Number Publication Date
ATE362374T1 true ATE362374T1 (de) 2007-06-15

Family

ID=23538715

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00955737T ATE362374T1 (de) 1999-09-03 2000-08-18 Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust

Country Status (14)

Country Link
US (1) US20060019887A1 (de)
EP (2) EP1140136B1 (de)
JP (2) JP2003508491A (de)
KR (1) KR20010085996A (de)
CN (1) CN1345246A (de)
AT (1) ATE362374T1 (de)
AU (1) AU6788900A (de)
CA (1) CA2349406C (de)
DE (1) DE60034871T2 (de)
ES (1) ES2287028T3 (de)
HU (1) HUP0104688A3 (de)
IL (1) IL142900A0 (de)
WO (1) WO2001017543A2 (de)
ZA (1) ZA200103565B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
JP2002509431A (ja) 1996-12-23 2002-03-26 イミュネックス・コーポレーション ＮＦ−κＢのレセプター活性化因子−レセプターはＴＮＦレセプタースーパーファミリーの一員である−
RU2238949C2 (ru) 1997-04-15 2004-10-27 Санкио Компани Лимитед Белок, специфически связывающийся с ингибирующим остеокластогенез фактором (ocif) (варианты), днк его кодирующая (варианты), днк в качестве зонда (варианты), способ получения белка (варианты), способ скрининга вещества (варианты), антитело (варианты), способ получения поликлонального антитела, гибридома (варианты), способ получения моноклонального антитела, способ измерения ocif-связывающего белка, фармацевтическая композиция (варианты) и лекарственное средство (варианты)
CZ302262B6 (cs) 1997-04-16 2011-01-19 Amgen Inc. Izolovaná nukleová kyselina, polypeptid kódovaný touto nukleovou kyselinou, expresní vektor obsahující tuto nukleovou kyselinu, hostitelská bunka transfekovaná tímto expresním vektorem, izolovaný protein vázající osteoprotegerin, protilátka vázající
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
EP2009025B1 (de) 1998-05-14 2011-07-27 Immunex Corporation Verfahren zur Hemmung der Wirkung der Osteoklasten
CA2347107A1 (en) * 1998-10-28 2000-05-04 Shinichi Mochizuki Bone-pathobolism treating agent
US20020090646A1 (en) * 2000-05-03 2002-07-11 Amgen Inc. Calcitonin-related molecules
ES2208145T3 (es) 2000-09-22 2007-12-16 Immunex Corporation Ensayos de seleccion para agonistas o antagonistas del receptor activador de nf-kb.
WO2002098362A2 (en) * 2001-06-06 2002-12-12 Immunex Corporation Use of rank antagonists to treat cancer
EP1270015A3 (de) * 2001-06-29 2004-02-25 Sankyo Company Limited Ein Komplex enthaltend OCIF und einem Polysaccharid
AU2003243139B2 (en) 2002-04-05 2007-06-21 Amgen Inc. Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
US7585840B2 (en) 2002-04-10 2009-09-08 Merck Serono S.A. Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
PL372928A1 (en) * 2002-04-10 2005-08-08 Applied Research Systems Ars Holding N.V. Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
US20050287603A1 (en) * 2002-06-07 2005-12-29 Gorczynski Reginald M Modulation of bone development
NZ554390A (en) 2004-12-13 2010-07-30 Cephalon Australia Vic Pty Ltd Osteoprotegerin variant proteins
TW200714289A (en) * 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
EP2952191B1 (de) * 2009-06-12 2018-08-22 Sunovion Pharmaceuticals Inc. Sublinguales apomorphin
CN102242209B (zh) * 2011-07-05 2013-12-11 北京大学人民医院 基于多个基因辅助诊断多发性骨髓瘤患者的定量检测试剂盒
MX357291B (es) * 2012-03-31 2018-07-04 R Pharm Cjsc Closed Joint Stock Company Composicion derivada de osteoprotegerina y su uso.
JP2017508792A (ja) * 2014-03-06 2017-03-30 アール−ファーム・オーバーシーズ・インコーポレイテッドＲ−Ｐｈａｒｍ Ｏｖｅｒｓｅａｓ， Ｉｎｃ． オステオプロテゲリンはランケル・インヒビターを引き出した
KR101576904B1 (ko) * 2014-07-31 2015-12-14 (주)케어젠 파골세포 분화 및 활성 억제능을 갖는 펩타이드 및 이의 용도
JP2020500306A (ja) * 2016-11-04 2020-01-09 オーフス ウニベルシテット 新生児Ｆｃ受容体の過剰発現により特徴づけられる腫瘍の同定と治療
CN110483647B (zh) * 2019-08-19 2021-02-09 重庆大学附属肿瘤医院 一种抗肿瘤多肽及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4710473A (en) * 1983-08-10 1987-12-01 Amgen, Inc. DNA plasmids
WO1988001213A1 (en) * 1986-08-18 1988-02-25 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents
FR2640537B1 (fr) * 1988-12-21 1992-02-21 Levy Guy Installation et procede utilisant l'effet laser, pour la coupe ou la vaporisation de materiaux et tissus divers
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
CA2082951C (en) * 1991-03-15 1999-12-21 Robert M. Platz Pulmonary administration of granulocyte colony stimulating factor
US5447851B1 (en) * 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
CA2131003A1 (en) * 1992-05-26 1993-12-09 Raymond G. Goodwin Novel cytokine that binds cd30
US5457035A (en) * 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US5843901A (en) * 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
US20050147611A1 (en) * 1995-12-22 2005-07-07 Amgen Inc. Combination therapy for conditions leading to bone loss
US7005413B1 (en) * 1995-12-22 2006-02-28 Amgen Inc. Combination therapy for conditions leading to bone loss
US6369027B1 (en) * 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
US6613544B1 (en) * 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US20030207827A1 (en) * 1995-12-22 2003-11-06 William J. Boyle Osteoprotegerin

Also Published As

Publication number Publication date
WO2001017543A3 (en) 2001-07-26
CN1345246A (zh) 2002-04-17
EP1800691A2 (de) 2007-06-27
EP1140136A2 (de) 2001-10-10
AU6788900A (en) 2001-04-10
DE60034871D1 (de) 2007-06-28
ZA200103565B (en) 2002-05-03
IL142900A0 (en) 2002-04-21
US20060019887A1 (en) 2006-01-26
DE60034871T2 (de) 2008-01-17
CA2349406C (en) 2011-01-11
HUP0104688A2 (hu) 2002-03-28
JP2003508491A (ja) 2003-03-04
HUP0104688A3 (en) 2004-07-28
WO2001017543A2 (en) 2001-03-15
CA2349406A1 (en) 2001-03-15
EP1800691A3 (de) 2007-10-31
ES2287028T3 (es) 2007-12-16
EP1140136B1 (de) 2007-05-16
KR20010085996A (ko) 2001-09-07
JP2011225581A (ja) 2011-11-10

Similar Documents

Publication Publication Date Title
ATE362374T1 (de) Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust
ATE296634T1 (de) (s,s)-reboxetin zur behandlung von fibromyalgie und anderen somatoformen störungen
DE60227095D1 (de) Zusammensetzungen und verfahren zur behandlung von abgebundenem gips
DE69942680D1 (de) Verfahren und Zusammensetzungen zur Prävention und Behandlung von Anämie
ATE282591T1 (de) Thioharnstoffverbindungen, zusammensetzungen sowie verfahren zur behandlung oder verhütung von entzündlichen erkrankungen und atherosklerose
DE60139689D1 (de) Kombination von CpG und Antikörpern gegen CD19,CD20,CD22 oder CD40 zur Prävention oder Behandlung von Krebs.
DE60023872D1 (de) Verfahren zur erhöhung der biologischen effektivität von zusammensetzungen zur pflanzenbehandlung
DE10082139T1 (de) Zusammensetzung zur Behandlung von Reibungspaaren
ATE448775T1 (de) Rifalazil zur behandlung von infektionen mit clostridium difficile
ATE414512T1 (de) Kombinationstherapie zur behandlung von krebs
DE60030554D1 (de) Verwendungen von et743 zur behandlung von krebs
DE60021908D1 (de) Hydroxyeicosatetraenoatsalze, zusammensetzungen und verfahren zur verwendung zur behandlung des trockenen auges
DE60220043D1 (de) Carbamatverbindungen zur vorbeugung oder behandlung von neurodegenerativen störungen
DE60139783D1 (de) Gen und pflanzenextrakte, wirksam zur behandlung und prävention von chlamydieninfektionen
DE69943089D1 (de) Methode zur behandlung von staphylokokkeninfektionen
ATE278441T1 (de) Verfahren zum auffinden von verbindungen, welche zur behandlung und/oder prophylaxe von obesitas geeignet sind
DE69941821D1 (de) Fluorenthaltende zusammensetzung zur behandlung von oberflächen
ATE473277T1 (de) Zusammensetzungen und verfahren zur prävention und behandlung von immunvermittelten entzündungskrankheiten
ATE415163T1 (de) Verfahren und zusammensetzungen zur behandlung von augenerkrankungen
DE60219658D1 (de) Verfahren zur prävention und behandlung von infektionen mit dem flavivirus bei tieren
DE602004028574D1 (de) Zusammensetzungen und verfahren zur behandlung des reizdarmsyndroms und von nichtulzeröser dyspepsie
DE60018704D1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
ATE347888T1 (de) Verwendung von aivlosin zur behandlung und prevention der lawsonia-infektionen in schweinen.
DE60331654D1 (de) Nicht-radioaktives Strontiummittel zur Behandlung von Krebs
DE60028831D1 (de) Zusammensetzungen und verfahren zur behandlung von epilepsie

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties